FIELD: medicine; oncology.
SUBSTANCE: Etoposide, Cisplatin, Aranose are administered one after another, in intraperitoneally, in a dose of 1/4 from the maximum tolerated dose with an interval of 10-20 minutes at a double or triple administration regimen.
EFFECT: inhibition of tumour growth at the expense of complex action of preparations and treatment tolerance increase.
4 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
LUNG CANCER THERAPY | 2008 |
|
RU2367436C1 |
METHOD OF TREATING LUNG CANCER | 2009 |
|
RU2414894C1 |
METHOD OF TREATING COLON CANCER | 2012 |
|
RU2529831C2 |
ANTICANCER PHARMACEUTICAL COMPOSITIONS AND METHOD OF TREATING BREAST CANCER | 2015 |
|
RU2581022C1 |
METHOD FOR TREATMENT OF SW620 HUMAN COLON CANCER IN EXPERIMENT | 2017 |
|
RU2665168C1 |
POLYMER CONTAINING MEDICINAL AGENT BASED ON ANTITUMOR AGENT ETOPOSIDE | 2015 |
|
RU2595859C1 |
PEPTIDE, POSSESSING ANTI-TUMOR AND ANTI-METASTATIC ACTIVITY, AND FINISHED DOSAGE FORM BASED THEREON | 2018 |
|
RU2682039C1 |
ORAL ANTITUMOUR DRUGS AND METHOD FOR ONCOLOGICAL DISEASES TREATMENT | 2016 |
|
RU2639479C1 |
COMBINATION OF DEHYDROXYMETHYL EPOXYQUINOMYCIN (DHMEQ) AND CYTOSTATICS FOR TREATING OVARIAN CANCER | 2018 |
|
RU2704020C1 |
METHOD FOR ENHANCING OF CYCLOPHOSPHAN ANTITUMOR AND ANTIMETASTATIC ACTIVITY IN EXPERIMENT | 2004 |
|
RU2270682C2 |
Authors
Dates
2009-08-27—Published
2008-04-29—Filed